Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Ipatasertib
Другие языки:

    Ipatasertib

    Подписчиков: 0, рейтинг: 0
    Ipatasertib
    Ipatasertib.svg
    Clinical data
    Routes of
    administration    		 PO
    ATC code
    • None
    Identifiers
    • (S)-2-(4-Chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
    CAS Number
    ChemSpider
    UNII
    KEGG
    Chemical and physical data
    Formula C24H32ClN5O2
    Molar mass 458.00 g·mol−1
    3D model (JSmol)
    • CC(C)NC[C@@H](C(=O)N1CCN(CC1)C1=C2[C@H](C)C[C@@H](O)C2=NC=N1)C1=CC=C(Cl)C=C1
    • InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1
    • Key:GRZXWCHAXNAUHY-NSISKUIASA-N

    Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of AKT, which is a key component of the PI3K/AKT pathway. It was discovered by Array Biopharma and is currently in phase II trials for treatment of breast cancer.

    In vitro, ipatasertib showed activity against all three isoforms of Akt.


    Новое сообщение